A 2026 RAND survey study estimates that approximately 4.8 million U.S. veterans have used psilocybin mushrooms, LSD, or MDMA. About half of those veterans reported uncertainty about whether telling a VA provider would put their benefits at risk. The findings are from a survey, not a clinical trial. Key takeaways Prevalence is substantial: Roughly 27.5% […]
A probability-based, nationally representative RAND survey of 10,122 US adults estimates that roughly 10 million Americans microdosed psilocybin, MDMA, or LSD in 2025, representing about 3.7 percent of the adult population. The survey is observational, and the evidence on benefit and safety remains mixed. Key takeaways Microdosing is no longer a fringe behavior. RAND’s weighted […]
A memo submitted to the Congressional Psychedelics Advancing Therapies Caucus, authored by Reason Foundation analysts, lays out five legislative approaches that could reduce scheduling barriers, expand use of real-world clinical data, and lower the cost of developing psychedelic therapies. This is a policy analysis document, not a clinical study. Key takeaways Schedule III reclassification of […]
A bipartisan bill introduced in Congress would permit licensed physicians to administer Schedule I controlled substances, including psilocybin and MDMA, to patients with serious or terminal illnesses. The proposal is a legislative development, not a clinical study, and no therapeutic outcomes data are attached to the bill itself. Key takeaways A legal pathway, not an […]
New research published in June 2026 in the Proceedings of the National Academy of Sciences offers one of the clearest mechanistic pictures yet of what several psychedelic compounds have in common inside the brain. Using optical flow analysis, a technique that tracks the direction and strength of neural signal movement across the cortex, scientists from […]